2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Infiltrative Disease of the Tubulointerstitium
Aklilu A, Luciano R. Infiltrative Disease of the Tubulointerstitium. 2022, 231-241. DOI: 10.1007/978-3-030-93438-5_18.Peer-Reviewed Original ResearchInfiltrative diseasePlasma cell disordersRenal cell carcinomaRenal tubular cellsWhite blood cellsCancer-targeted therapyKidney injuryPrimary malignancySecondary inflammationTubular damageTubulointerstitial nephritisBronchogenic carcinomaInfiltrative lesionsLymphoproliferative disordersCell carcinomaMetastatic spreadBreast cancerPrimary involvementNormal kidneySolid cancersCell disordersTubular cellsTubular lumenBlood cellsDisease